Wall Street Zen Downgrades Solventum (NYSE:SOLV) to Hold

Solventum (NYSE:SOLV) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other research analysts also recently weighed in on SOLV. KeyCorp upped their price target on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. UBS Group boosted their price objective on Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, August 6th. BMO Capital Markets initiated coverage on Solventum in a report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price objective for the company. Mizuho set a $113.00 target price on Solventum in a report on Thursday, August 6th. Finally, Piper Sandler lifted their price target on shares of Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.64.

Solventum Stock Up 0.1%

Shares of NYSE SOLV opened at $89.64 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The firm has a market cap of $15.26 billion, a PE ratio of 10.96, a P/E/G ratio of 1.15 and a beta of 0.60. The company’s fifty day simple moving average is $80.91 and its 200 day simple moving average is $75.03. Solventum has a 12-month low of $62.38 and a 12-month high of $90.00.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business’s revenue was up 2.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, sell-side analysts forecast that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Independent Franchise Partners LLP lifted its position in shares of Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after purchasing an additional 2,456,451 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Solventum in the 2nd quarter worth about $150,066,000. Norges Bank purchased a new stake in Solventum in the 4th quarter valued at about $147,467,000. Diamond Hill Capital Management Inc. increased its stake in Solventum by 152.2% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares during the last quarter. Finally, Boston Partners increased its stake in Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.